Adalimumab, a monoclonal antibody against TNF-α, is highly effective in moderate-to-severe plaque psoriasis and psoriatic arthritis, improving Psoriasis Area and Severity Index (PASI) scores and patient quality of life [11]. This evidence concerns the gene TNF and psoriasis vulgaris.